Journal of Vaccine Research 2024, Vol.14, No.6, 307-315 http://medscipublisher.com/index.php/jvr 307 Research Insight Open Access Comparative Analysis of Bivalent, Quadrivalent, and Nonavalent HPV Vaccines Caijuan Shou, Xiaoping Cai Xiongcheng Jianmin Med. Ltd., Zhuji, 311800, China Corresponding author email: 2985757244@qq.com Journal of Vaccine Research, 2024, Vol.14, No.6 doi: 10.5376/jvr.2024.14.0029 Received: 11 Oct., 2024 Accepted: 20 Nov., 2024 Published: 15 Dec., 2024 Copyright © 2024 Shou and Cai, This is an open access article published under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited Preferred citation for this article: Shou C.J., and Cai X.P., 2024, Comparative analysis of bivalent, quadrivalent, and nonavalent HPV vaccines, Journal of Vaccine Research, 14(6): 307-315 (doi: 10.5376/jvr.2024.14.0029) Abstract Comparing the bivalent, quadrivalent, and nine-valent HPV vaccines is important for finding the best way to prevent HPV-related diseases, especially cervical cancer. This study looked at how HPV spreads, how the three vaccines work in the body, and which HPV types they cover. It also looked at what diseases each vaccine can help prevent. The research focused on how well each vaccine works, how long the protection lasts, and how safe and well-tolerated they are in different groups of people. The study also went into detail about how each vaccine performs in real-world use. In addition, the study reviewed how the vaccines are given and how cost-effective they are. It compared their value in different settings, looking at both economic factors and medical outcomes. The study also looked at how countries around the world promote these vaccines, including national policies and differences in coverage between regions. The results show why vaccine innovation, better vaccine schedules, and fair access are all important in the fight against HPV. Future work should focus on making vaccines that protect against more types of HPV, improving how vaccines are given, and helping more countries work together to make vaccines easier to get and more effective. This study gives useful information for planning HPV vaccination and supports global efforts to prevent and control cervical cancer. Keywords HPV vaccines; Bivalent; Quadrivalent; Nonavalent; Cervical cancer prevention 1 Introduction Human papillomavirus (HPV) infection is a common global health issue. It is the primary cause of cervical cancer, especially HPV types 16 and 18, which are found in most cervical cancer cases (Kim et al., 2023). The infection rate varies across regions, but overall, HPV remains one of the leading causes of cervical cancer and cervical intraepithelial neoplasia (CIN). It is also associated with certain genital and oropharyngeal cancers, highlighting the importance of prevention. The introduction of vaccines has been a major step forward in HPV prevention. The bivalent vaccine (2v-HPV) protects against HPV types 16 and 18. The quadrivalent vaccine (4v-HPV) adds coverage for types 6 and 11, which are common causes of genital warts (Beyer and Osterhaus, 2020). The nonavalent vaccine (9v-HPV) provides even broader protection, covering five additional high-risk types: HPV 31, 33, 45, 52, and 58. Since each vaccine covers different types, comparing them helps public health professionals make more suitable choices. There are several advantages to comparing the three vaccines. It helps evaluate their effectiveness against various HPV types (Lin et al., 2023) and assess their cross-protection ability—especially for the bivalent and quadrivalent vaccines (Stanley et al., 2021). This information is valuable for clinicians and public health decision-makers, allowing them to choose the most appropriate vaccine based on the common HPV types in their region. This study focuses on comparing the protective effects, cross-protection, and disease prevention performance of the three HPV vaccines. Data from clinical trials and other research are used to analyze the strengths and limitations of each vaccine. The goal is to provide evidence-based guidance for public health policies and vaccination programs, ultimately aiming to reduce the global burden of HPV-related diseases. 2 Basic Principles and Coverage of HPV Vaccines 2.1 Structural characteristics of HPV and the immune mechanism of vaccines Human papillomavirus (HPV) is a DNA virus with a circular, double-stranded genome. It mainly infects skin and mucosal cells, especially in the genital area. HPV is well known for causing cervical cancer, but it can also lead to
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==